Business Context and Reporting Period
Akers Biosciences, Inc. (the "Company") filed this Form 8-K on January 10, 2017, reporting events occurring on January 9, 2017. The Company, incorporated in New Jersey, entered into an underwriting agreement for an underwritten public offering of its common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 1,667,000 shares of Common Stock and five-year warrants to purchase up to 833,500 shares.
- Offering Price: $1.20 per Share and half-Warrant.
- Warrant Terms: Exercise price of $1.50 per share.
- Gross Proceeds: Approximately $2,000,400 (or approximately $2,147,400 if the over-allotment option is exercised in full).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 122,500 Shares and/or 61,250 Warrants.
- Use of Proceeds: Growth and working capital, including new diagnostic products, fulfilling purchase orders, customer development, R&D, and general corporate purposes.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.
Material Changes and Agreements
The primary material change is the entry into a definitive underwriting agreement with Joseph Gunnar & Co., LLC. Key contractual terms include:
- Lock-Up Agreement: The Company, directors, and executive officers agreed not to sell, transfer, or dispose of securities for a six-month period following the agreement date, subject to certain exceptions and extensions.
- Closing Date: Expected on or about January 13, 2017, subject to customary closing conditions.
- Registration Basis: The offering is made pursuant to an existing shelf registration statement on Form S-3 (File No. 333-214214).
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to expand research and development initiatives and introduce new diagnostic products to the market. The filing notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The Company issued a press release on January 9, 2017, announcing the pricing of the Offering.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 13, 2017) and whether the over-allotment option was exercised.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 4.1) for specific covenants and limitations.
- Confirm the actual net proceeds after deducting underwriting discounts and offering expenses.
- Monitor the Company's progress in deploying capital toward the stated uses, specifically new diagnostic product introductions and R&D.
- Check for any subsequent filings regarding the exercise of the 45-day over-allotment option.